Holen Sie sich die Stockscreener-App
4.92
3.58%
0.17
Schlusskurs vom Vortag:
$4.75
Offen:
$4.77
24-Stunden-Volumen:
1.25M
Relative Volume:
0.86
Marktkapitalisierung:
$493.48M
Einnahmen:
$775.09M
Nettoeinkommen (Verlust:
$-58.68M
KGV:
-37.10
EPS:
-0.1326
Netto-Cashflow:
$64.06M
1W Leistung:
+3.58%
1M Leistung:
+6.96%
6M Leistung:
+4.46%
1J Leistung:
-44.90%
1-Tages-Spanne:
$4.77
$4.97
1-Wochen-Bereich:
$4.68
$4.97
52-Wochen-Spanne:
$3.675
$9.2599
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Vergleichen Sie GDRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
4.92 | 1.70B | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
285.20 | 45.64B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
61.08 | 9.68B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
97.41 | 8.32B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
59.38 | 11.63B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
36.57 | 6.57B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
Jim Cramer Holds Back on GoodRx (GDRX) - MSN
Google, Meta Can't Escape GoodRx Health Data Sharing Suit - Law360
What analysts say about GoodRx Holdings Inc. stockSky-high return potential - jammulinksnews.com
What drives GoodRx Holdings Inc. stock priceHigh-yield investments - jammulinksnews.com
Is GoodRx Holdings Inc. a good long term investmentExceptional profit potential - jammulinksnews.com
GoodRx Holdings Inc. Stock Analysis and ForecastHigh-octane financial growth - jammulinksnews.com
GOODRX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of GoodRx Holdings, Inc.GDRX - The Globe and Mail
User - FinancialContent
Is GoodRx Holdings Inc. stock a good hedge against inflationChart Based Entries - Newser
Why GoodRx Holdings Inc. stock attracts strong analyst attentionSolid Return Trade Selections - beatles.ru
OPRX Vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum? - Barchart.com
OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum? - Yahoo Finance
What makes GoodRx Holdings Inc. stock price move sharplyBig Profit Small Risk Alerts - Newser
Riot Platforms selling more Bitfarms (BITF) - The Globe and Mail
Leerink Partners Remains Bullish on GoodRx Holdings (GDRX) - Insider Monkey
Undervalued Opportunities: Penny Stocks Worth Watching In July 2025 - simplywall.st
GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of “Moderate Buy” by Analysts - Defense World
GoodRx Holdings Announces Q2 2025 Financial Results Release Date - AInvest
GoodRx Announces Date for Second Quarter 2025 Earnings Release and Conference Call - Business Wire
GDRX vs. HQY: Which Stock Is the Better Value Option? - Yahoo Finance
GoodRx: A One Big Beautiful Bill Act Beneficiary - Seeking Alpha
KeyBanc Maintains Overweight Rating on GoodRx (GDRX) - MSN
While institutions own 22% of GoodRx Holdings, Inc. (NASDAQ:GDRX), individual investors are its largest shareholders with 48% ownership - Yahoo Finance
GoodRx Holdings, Inc. (GDRX) Stock Analysis: Exploring a Potential 26.84% Upside for Investors - DirectorsTalk Interviews
GoodRx (GDRX) Unveils Lifecycle to Enhance Engineering Methodologies - Yahoo Finance
GoodRx Has New Service For ED Meds - Los Angeles Business Journal
GoodRx (GDRX) Launches a New Subscription Service for Erectile Dysfunction Treatment - Insider Monkey
GoodRx launches new subscription service focused on erectile dysfunction treatments - MSN
High Growth Tech Stocks In The US To Watch This June 2025 - simplywall.st
GoodRx (GDRX) Expands Services with New Subscription for ED Trea - GuruFocus
GoodRx (GDRX) Expands Services with New Subscription for ED Treatment | GDRX Stock News - GuruFocus
GoodRx (GDRX) Shares Rise with Launch of Erectile Dysfunction Subscription Service - GuruFocus
GoodRx stock gains on new subscription service (GDRX:NASDAQ) - Seeking Alpha
GoodRx (GDRX) Introduces Subscription Service for ED Treatment | - GuruFocus
GoodRx (GDRX) Introduces Subscription Service for ED Treatment | GDRX Stock News - GuruFocus
GoodRx Launches New Erectile Dysfunction Subscription Service to Simplify Access and Eliminate Treatment Barriers - marketscreener.com
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.73%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):